To further confirm that the BiTE targets PDL1+ tumor cells regardless of the type of tumor, constitutively PDL1+ H358 lung adenocarcinoma cells and MDA-MB-231 breast cancer cells (Figure 4C) were also tested and exhibited >45% tumor cell death (Figure 4D). This evidence concerns the gene CD274 and neoplasm.